BMY Bristol-Myers Squibb Company Common Stock
$67,40
السعر · أغسطس 25, 2026
البيانات الأساسية اعتبارًا من يوليو 30, 2026
نطاق 52 أسبوعًا
$43–$69
95% of range
تقييم المحللين
HOLD
35 analysts
السعر المستهدف
$66
P/E (TTM)
15.6
ROE
40.5%
هامش صافي الربح
14.6%
حول Bristol-Myers Squibb Company Common Stock نظرة عامة على الشركة من ويكيبيديا
بريستول-مايرز سكويب هي شركة دواء أمريكية يقع مقرها في مدينة نيويورك. تقوم الشركة بتصنيع الأدوية في العديد من المجالات العلاجية بما في ذلك: السرطان، فيروس نقص المناعة، الأمراض القلبية الوعائية، السكري، التهاب الكبد، التهاب المفاصل والاضطرابات النفسية. وتتمثل مهمتها في «اكتشاف وتطوير وتوزيع الأدوية المبتكرة التي تساعد المرضى في التغلب على الأمراض الخطيرة». في سبتمبر 2020، وصل العائدات السنوية للشركة إلى 39.3 مليار دولار.
اقرأ المزيد
بريستول-مايرز سكويب (الإنجليزية: Bristol-Myers Squibb) هي شركة دواء أمريكية يقع مقرها في مدينة نيويورك. تقوم الشركة بتصنيع الأدوية في العديد من المجالات العلاجية بما في ذلك: السرطان، فيروس نقص المناعة، الأمراض القلبية الوعائية، السكري، التهاب الكبد، التهاب المفاصل والاضطرابات النفسية. وتتمثل مهمتها في «اكتشاف وتطوير وتوزيع الأدوية المبتكرة التي تساعد المرضى في التغلب على الأمراض الخطيرة». في سبتمبر 2020، وصل العائدات السنوية للشركة إلى 39.3 مليار دولار.
== المراجع ==
المصدر: ويكيبيديا, CC BY-SA 4.0 · عرض على ويكيبيديا ↗
BMY لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
السعر
$67.40
القيمة السوقية
—
P/E (TTM)
15.6
ربح السهم (آخر 12 شهرًا)
$3.46
الإيرادات (آخر 12 شهرًا)
$48.19B
عائد التوزيعات
—
ROE
40.5%
D/E الدين/حقوق الملكية
2.5
نطاق 52 أسبوعًا
$43 – $69
BMY مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
Configure
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
الإيرادات وصافي الدخل
$48.19B
2019-12-31
→
2025-12-31
ربح السهم
$3.46
2019-12-31
→
2025-12-31
التدفق النقدي الحر
$12.85B
2019-12-31
→
2025-12-31
الهوامش
14.6%
2019-12-31
→
2020-12-31
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
المقياس
اتجاه 5 سنوات
BMY
متوسط الأقران
P/E (TTM)
15.6
32.1
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
المقياس
اتجاه 5 سنوات
BMY
متوسط الأقران
Net Profit Margin (هامش صافي الربح)
14.6%
13.0%
ROA (العائد على الأصول)
7.7%
6.4%
ROE
40.5%
15.1%
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
المقياس
اتجاه 5 سنوات
BMY
متوسط الأقران
Debt / Equity (الدين / حقوق الملكية)
2.5
—
Current Ratio (النسبة الحالية)
1.3
1.6
Quick Ratio (النسبة السريعة)
0.8
—
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
المقياس
اتجاه 5 سنوات
BMY
متوسط الأقران
Revenue YoY (الإيرادات مقارنة بالعام السابق)
-0.22%
—
Revenue CAGR 3Y (معدل نمو الإيرادات السنوي المركب لـ 3 سنوات)
1.5%
—
Revenue CAGR 5Y (معدل نمو الإيرادات السنوي المركب لـ 5 سنوات)
2.5%
—
EPS YoY (ربحية السهم على أساس سنوي)
30.9%
—
Net Income YoY (صافي الدخل مقارنة بالعام السابق)
26.8%
—
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
المقياس
اتجاه 5 سنوات
BMY
متوسط الأقران
Payout Ratio (نسبة التوزيع)
71.5%
—
التوزيعات العائد، نسبة التوزيع، تاريخ توزيع الأرباح، معدل النمو السنوي المركب لمدة 5 سنوات
عائد الأرباح
—
نسبة التوزيع
71.5%
5Y Div CAGR
—
| تاريخ الاستحقاق | المبلغ |
|---|---|
| 2 يوليو، 2026 | $0,6300 |
| 2 إبريل، 2026 | $0,6300 |
| 2 يناير، 2026 | $0,6300 |
| 3 أكتوبر، 2025 | $0,6200 |
| 3 يوليو، 2025 | $0,6200 |
| 4 إبريل، 2025 | $0,6200 |
| 3 يناير، 2025 | $0,6200 |
| 4 أكتوبر، 2024 | $0,6000 |
| 5 يوليو، 2024 | $0,6000 |
| 4 إبريل، 2024 | $0,6000 |
| 4 يناير، 2024 | $0,6000 |
| 5 أكتوبر، 2023 | $0,5700 |
| 6 يوليو، 2023 | $0,5700 |
| 6 إبريل، 2023 | $0,5700 |
| 5 يناير، 2023 | $0,5700 |
| 6 أكتوبر، 2022 | $0,5400 |
| 30 يونيو، 2022 | $0,5400 |
| 31 مارس، 2022 | $0,5400 |
| 6 يناير، 2022 | $0,5400 |
| 30 سبتمبر، 2021 | $0,4900 |
BMY توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
شراء
35 محللين
- شراء قوي 6 17,1%
- شراء 8 22,9%
- احتفاظ 19 54,3%
- بيع 2 5,7%
- بيع قوي 0 0,0%
السعر المستهدف لمدة 12 شهرًا
24 محللين · 2026-08-24
الوسيط
$68.00
الآن
$67.40
منخفض
$40.00
مرتفع
$80.00
السعر المستهدف الوسيط
$68.00
+0,9%
السعر المستهدف المتوسط
$66.21
-1,8%
سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
متوسط المفاجأة
0.25%
| الفترة | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|
| 30 يونيو، 2026 | $2.04 | $1.60 | 0.44% |
| 31 مارس، 2026 | $1.58 | $1.43 | 0.15% |
| 31 ديسمبر، 2025 | $1.26 | $1.13 | 0.13% |
| 30 سبتمبر، 2025 | $1.63 | $1.52 | 0.11% |
| 30 يونيو، 2025 | $1.46 | $1.08 | 0.38% |
| 31 مارس، 2025 | $1.80 | $1.51 | 0.29% |
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| BMY | — | 15.6 | -0.22% | 14.6% | 40.5% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
| JNJ | — | 18.8 | 6.0% | 28.5% | 35.0% | 67.9% |
| MRK | — | 14.5 | 1.3% | 28.1% | 36.9% | — |
| PFE | — | 18.3 | -1.7% | 12.4% | 8.9% | — |
| RPRX | — | 21.7 | 5.1% | 32.4% | 8.0% | — |
| ZTS | $53.46B | 20.9 | 2.3% | 28.2% | 66.0% | — |
| VTRS | — | -4.2 | -3.0% | -24.6% | -23.2% | 35.1% |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل 17
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B | $19.43B | $16.56B | $15.88B | |
| Cost of Revenue | $13.94B | $13.97B | $10.69B | $10.14B | $9.94B | $11.77B | $8.08B | $6.47B | $6.01B | $4.97B | $3.91B | $3.93B | |
| Gross Profit | · | · | · | · | · | $30.75B | $18.07B | $16.09B | $14.68B | $14.48B | $12.65B | $11.95B | |
| R&D Expense | $9.95B | $11.16B | $9.30B | $9.51B | $10.20B | $10.05B | $6.15B | $6.33B | $6.47B | $5.01B | $5.92B | $4.53B | |
| SG&A Expense | $7.27B | $8.41B | $7.77B | $7.81B | $7.69B | $7.66B | $4.87B | $4.55B | $4.75B | $4.98B | $4.84B | $4.82B | |
| Operating Expenses | $38.87B | $56.68B | $36.57B | $38.45B | $38.29B | $49.39B | $21.17B | $16.59B | $15.64B | $13.51B | $14.48B | $13.50B | |
| Interest Expense | · | · | $1.17B | $1.23B | $1.33B | $1.42B | $656M | $183M | $196M | $167M | $184M | $203M | |
| Interest Income | $586M | $478M | $449M | $171M | $39M | $121M | $464M | $173M | $126M | $97M | $101M | $101M | |
| Other Non-op | $-674M | $-893M | $1.16B | $-576M | $720M | $2.31B | $-938M | $854M | $1.69B | $1.45B | $187M | $-210M | |
| Pretax Income | $9.33B | $-8.38B | $8.44B | $7.71B | $8.10B | $-6.87B | $4.97B | $5.97B | $5.13B | $5.92B | $2.08B | $2.38B | |
| Income Tax | $2.27B | $554M | $400M | $1.37B | $1.08B | $2.12B | $1.51B | $1.02B | $4.16B | $1.41B | $446M | $352M | |
| Net Income | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B | $-9.02B | $3.44B | $4.92B | $1.01B | $4.46B | $1.56B | $2.00B | |
| EPS (Basic) | $3.47 | $-4.41 | $3.88 | $2.97 | $3.15 | $-3.99 | $2.02 | $3.01 | $0.61 | $2.67 | $0.94 | $1.21 | |
| EPS (Diluted) | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 | $-3.99 | $2.01 | $3.01 | $0.61 | $2.65 | $0.93 | $1.20 | |
| Shares (Basic) | 2,034,000,000 | 2,027,000,000 | 2,069,000,000 | 2,130,000,000 | 2,221,000,000 | 2,258,000,000 | 1,705,000,000 | 1,633,000,000 | 1,645,000,000 | 1,671,000,000 | 1,667,000,000 | 1,657,000,000 | |
| Shares (Diluted) | 2,039,000,000 | 2,027,000,000 | 2,078,000,000 | 2,146,000,000 | 2,245,000,000 | 2,258,000,000 | 1,712,000,000 | 1,637,000,000 | 1,652,000,000 | 1,680,000,000 | 1,679,000,000 | 1,670,000,000 | |
| EBITDA | $4.01B | $9.60B | $9.76B | $10.28B | $10.69B | $10.38B | $1.75B | $637M | $789M | $382M | $376M | $467M |
الميزانية العمومية 31
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.21B | $10.35B | $11.46B | $9.12B | $13.98B | $14.55B | $12.35B | $6.91B | $5.42B | $4.24B | $2.38B | $5.57B | |
| Short-term Investments | · | · | · | $130M | $2.99B | $1.28B | $3.05B | $1.85B | $1.39B | $2.11B | $1.89B | $1.86B | |
| Receivables | $9.59B | $9.01B | $8.88B | $8.15B | $7.98B | $7.22B | $6.48B | $4.64B | $4.35B | $3.77B | $2.95B | $2.10B | |
| Inventory | $2.69B | $2.56B | $2.66B | $2.34B | $2.10B | $2.07B | $4.29B | $1.20B | $1.17B | $1.24B | $1.22B | $1.56B | |
| Prepaid Expense | · | · | · | · | · | · | · | · | $576M | $570M | $625M | $470M | |
| Other Current Assets | $4.61B | $5.62B | $5.91B | $5.79B | $4.83B | $3.79B | $1.98B | $2.02B | $576M | $570M | $625M | $470M | |
| Current Assets | $29.39B | $29.78B | $31.77B | $27.27B | $33.26B | $30.19B | $29.35B | $17.72B | $14.85B | $13.70B | $10.41B | $14.61B | |
| PP&E (Net) | $7.54B | $7.14B | $6.65B | $6.25B | $6.05B | $5.89B | $6.25B | $5.03B | $5.00B | $4.98B | $4.41B | $4.42B | |
| PP&E (Gross) | $12.84B | $12.09B | $11.45B | $10.42B | $10.08B | $9.47B | $10.21B | $8.85B | $8.99B | $9.17B | $8.63B | $9.07B | |
| Accum. Depreciation | $5.29B | $4.95B | $4.80B | $4.16B | $4.03B | $3.58B | $3.96B | $3.82B | $3.99B | $4.19B | $4.22B | $4.65B | |
| Goodwill | $21.75B | $21.72B | $21.17B | $21.15B | $20.50B | $20.55B | $22.49B | $6.54B | $6.86B | $6.88B | $6.88B | $7.03B | |
| Intangibles | $19.10B | $23.31B | $27.07B | $35.86B | $42.53B | $53.24B | $63.97B | $1.09B | $1.21B | $1.39B | $1.42B | $1.75B | |
| Other Non-current Assets | $6.47B | $6.11B | $5.37B | $4.94B | $5.54B | $7.02B | $6.60B | $2.02B | $1.53B | $1.05B | $1.12B | $621M | |
| Total Assets | $90.04B | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B | $129.94B | $34.99B | $33.55B | $33.71B | $31.75B | $33.75B | |
| Accounts Payable | $3.58B | $3.60B | $3.26B | $3.04B | $2.95B | $2.71B | $2.44B | $1.89B | $2.25B | $1.66B | $1.56B | $2.49B | |
| Accrued Liabilities | · | · | · | · | · | · | · | $6.49B | $6.01B | $5.27B | $4.74B | $2.46B | |
| Short-term Debt | $2.26B | $2.05B | $3.12B | $4.26B | $4.95B | $2.34B | $3.35B | $1.70B | $987M | $109M | $139M | $590M | |
| Current Liabilities | $23.42B | $23.77B | $22.26B | $21.89B | $21.87B | $19.08B | $18.30B | $10.65B | $9.56B | $8.84B | $8.02B | $8.46B | |
| Capital Leases | $1.83B | $1.37B | $1.53B | $1.26B | $874M | $833M | $672M | $0 | · | · | · | · | |
| Deferred Tax | $222M | $369M | $338M | $2.17B | $4.50B | $5.41B | $6.45B | $19M | $45M | $47M | $31M | $60M | |
| Other Non-current Liabilities | $5.04B | $4.47B | $6.42B | $6.59B | $7.33B | $7.78B | $10.10B | $4.54B | $1.16B | $1.28B | $1.43B | $618M | |
| Total Liabilities | $71.53B | $76.22B | $65.67B | $65.70B | $73.31B | $80.60B | $78.25B | $20.86B | $21.70B | $17.36B | $17.32B | $18.77B | |
| Long-term Debt | $44.83B | $49.43B | $39.53B | $38.95B | $44.37B | $50.34B | $46.15B | $6.89B | $6.97B | $6.46B | · | · | |
| Total Debt | $47.09B | $51.48B | $42.65B | $43.22B | $49.32B | $52.68B | $49.50B | $8.60B | $7.49B | $7.46B | $6.69B | $7.83B | |
| Common Stock | · | · | · | $292M | $292M | $292M | $292M | $221M | $221M | $221M | $221M | $221M | |
| Paid-in Capital | $46.39B | $46.02B | $45.68B | $45.16B | $44.36B | $44.33B | $43.71B | $2.08B | $1.90B | $1.73B | $1.46B | $1.51B | |
| Retained Earnings | $16.90B | $14.91B | $28.77B | $25.50B | $23.82B | $21.28B | $34.47B | $34.06B | $31.16B | $33.51B | $31.61B | $32.54B | |
| Treasury Stock | $43.58B | $43.66B | $43.77B | $38.62B | $31.26B | $26.24B | $25.36B | $19.57B | $19.25B | $16.78B | $16.56B | $16.99B | |
| AOCI | $-1.52B | $-1.24B | $-1.55B | $-1.28B | $-1.27B | $-1.84B | $-1.52B | $-2.76B | $-2.29B | $-2.50B | $-2.47B | $-2.42B | |
| Stockholders' Equity | $18.47B | $16.34B | $29.43B | $31.06B | $35.95B | $37.82B | $51.60B | $14.03B | $11.74B | $16.18B | $14.27B | $14.85B | |
| Liabilities + Equity | $90.04B | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B | $129.94B | $34.99B | $33.55B | $33.71B | $31.75B | $33.75B |
التدفق النقدي 19
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4.01B | $9.60B | $9.76B | $10.28B | $10.69B | $10.38B | $1.75B | $637M | $789M | $382M | $376M | $467M | |
| Stock-based Comp | $553M | $507M | $518M | $457M | $583M | $779M | $441M | $221M | $199M | $205M | $235M | $213M | |
| Deferred Tax | $-965M | $-2.09B | $-3.29B | $-2.74B | $-1.39B | $983M | $-924M | $45M | $453M | $-204M | $-347M | $-542M | |
| Amort. of Intangibles | $3.50B | $9.00B | $9.20B | $9.70B | $10.20B | $9.90B | $1.30B | $198M | $190M | $178M | $183M | $286M | |
| Restructuring | $563M | $635M | $365M | $75M | $169M | $530M | $301M | $131M | $293M | $109M | $118M | $163M | |
| Other Non-cash | $3.50B | $16.12B | $-1.16B | $-1.26B | $-663M | $10.93B | $3.37B | $76M | $2.27B | $-1.99B | $3M | $1.01B | |
| Operating Cash Flow | $14.16B | $15.19B | $13.86B | $13.07B | $16.21B | $14.05B | $8.21B | $7.07B | $5.28B | $3.06B | $2.10B | $3.15B | |
| CapEx | $1.31B | $1.25B | $1.21B | $1.12B | $973M | $753M | $836M | $951M | $1.05B | $1.22B | $820M | $526M | |
| Investing Cash Flow | $-4.13B | $-21.35B | $-2.29B | $-1.06B | $-538M | $-10.86B | $-9.91B | $-2.00B | $-66M | $1.48B | $-1.57B | $1.22B | |
| Debt Issued | $5.74B | $12.88B | $4.46B | $5.93B | $0 | $6.95B | $26.78B | $0 | $1.49B | $0 | $1.27B | · | |
| Net Debt Issued | $-5.20B | $10.01B | $576M | $-5.50B | $-6.02B | $4.20B | $17.52B | $-5M | $264M | $-15M | $-689M | $-676M | |
| Stock Repurchased | $0 | $0 | $5.16B | $8.00B | $6.29B | $1.55B | $7.30B | $320M | $2.47B | $231M | · | · | |
| Net Stock Activity | $0 | $0 | $-5.16B | $-8.00B | $-6.29B | $-1.55B | $-7.30B | $-320M | $-2.47B | $-231M | · | · | |
| Dividends Paid | $5.04B | $4.86B | $4.74B | $4.63B | $4.40B | $4.08B | $2.68B | $2.61B | $2.58B | $2.55B | $2.48B | $2.40B | |
| Financing Cash Flow | $-10.35B | $5.13B | $-9.42B | $-16.96B | $-16.22B | $-1.15B | $7.62B | $-3.54B | $-4.08B | $-2.65B | $-3.62B | $-2.44B | |
| Net Change in Cash | $-129M | $-1.17B | $2.19B | $-4.99B | $-657M | $2.15B | $5.91B | $1.49B | $1.18B | $1.85B | $-3.19B | $1.99B | |
| Taxes Paid | $3.26B | $3.90B | $4.30B | $5.40B | $3.50B | $3.40B | $1.50B | $747M | $546M | $2.00B | $577M | $544M | |
| Free Cash Flow | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B | $13.30B | $7.23B | $4.99B | $4.22B | $1.64B | $1.01B | $2.62B | |
| Levered FCF | · | · | $11.54B | $10.93B | $14.08B | $11.44B | $6.77B | $4.84B | $4.18B | $1.51B | $868M | $2.45B |
الربحية 6
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 72.3% | 69.1% | 71.0% | 70.8% | 74.5% | 76.4% | 75.2% | |
| Net Margin | 14.6% | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% | 13.2% | 21.8% | 4.9% | 22.9% | 9.4% | 12.6% | |
| Pretax Margin | 19.4% | -17.3% | 18.8% | 16.7% | 17.5% | -16.2% | 19.0% | 26.5% | 24.7% | 30.4% | 12.5% | 15.0% | |
| EBITDA Margin | 8.3% | 19.9% | 21.7% | 22.3% | 23.0% | 24.4% | 6.7% | 2.8% | 3.8% | 2.0% | 2.3% | 2.9% | |
| ROA | 7.7% | -9.5% | 8.4% | 6.1% | 6.1% | -7.4% | 3.7% | 14.3% | 3.0% | 13.2% | 4.9% | 6.0% | |
| ROE | 40.5% | -39.1% | 26.5% | 18.9% | 19.0% | -20.2% | 10.5% | 38.2% | 7.2% | 29.3% | 10.8% | 13.4% |
السيولة والملاءة 4
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.3 | 1.4 | 1.2 | 1.5 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.3 | 1.7 | |
| Quick Ratio | 0.8 | 0.8 | 0.9 | 0.8 | 1.1 | 1.2 | 1.2 | 1.3 | 1.2 | 1.1 | 0.9 | 1.1 | |
| Debt / Equity | 2.5 | 3.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.0 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | |
| LT Debt / Equity | 2.3 | 2.9 | 1.2 | 1.1 | 1.1 | 1.3 | 0.8 | 0.4 | 0.6 | 0.4 | 0.5 | 0.5 |
الكفاءة 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.3 | 0.3 | 0.7 | 0.6 | 0.6 | 0.5 | 0.5 | |
| Inventory Turnover | 5.3 | 5.4 | 4.3 | 4.6 | 4.8 | 3.7 | 2.9 | 5.5 | 5.0 | 4.0 | 2.8 | 2.6 | |
| Receivables Turnover | 5.2 | 5.4 | 5.3 | 5.7 | 6.1 | 6.2 | 4.7 | 5.0 | 5.1 | 5.8 | 6.6 | 8.4 |
معدلات النمو 8
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.22% | 7.3% | -2.5% | -0.49% | 9.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 1.5% | 1.4% | 1.9% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 2.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | · | 30.9% | -5.5% | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 5.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | · | 26.8% | -9.5% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 3.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 4.4% | · | · | · | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا) 6
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B | $19.43B | $16.56B | $15.88B | |
| Net Income TTM | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B | $-9.02B | $3.44B | $4.92B | $1.01B | $4.46B | $1.56B | $2.00B | |
| P/E | 15.6 | -12.8 | 13.3 | 24.4 | 20.0 | -15.5 | 31.9 | 17.3 | 100.5 | 22.1 | 74.0 | 49.2 | |
| Earnings Yield | 6.4% | -7.8% | 7.5% | 4.1% | 5.0% | -6.4% | 3.1% | 5.8% | 1.0% | 4.5% | 1.4% | 2.0% | |
| Payout Ratio | 71.5% | -54.4% | 59.1% | 73.2% | 62.8% | -45.2% | 77.9% | 53.1% | 255.9% | 57.1% | 158.3% | 119.7% | |
| Annual Payout | $5.04B | $4.86B | $4.74B | $4.63B | $4.40B | $4.08B | $2.68B | $2.61B | $2.58B | $2.55B | $2.48B | $2.40B |
قائمة الدخل 16
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.97B | $11.49B | $12.50B | $12.22B | $12.27B | $11.20B | $12.34B | $11.89B | $12.20B | $11.87B | $11.48B | $10.97B | $11.23B | $11.34B | $11.41B | $11.22B | |
| Cost of Revenue | $3.73B | $3.42B | $4.10B | $3.44B | $3.37B | $3.03B | $4.81B | $2.96B | $3.27B | $2.93B | $2.75B | $2.51B | $2.88B | $2.57B | $2.59B | $2.35B | |
| R&D Expense | $2.96B | $2.65B | $2.59B | $2.53B | $2.58B | $2.26B | $3.19B | $2.37B | $2.90B | $2.69B | $2.48B | $2.24B | $2.26B | $2.32B | $2.51B | $2.42B | |
| SG&A Expense | $1.83B | $1.62B | $2.18B | $1.79B | $1.71B | $1.58B | $2.14B | $1.98B | $1.93B | $2.37B | $2.07B | $2.00B | $1.93B | $1.76B | $2.27B | $1.93B | |
| Operating Expenses | $8.89B | $8.25B | $11.03B | $9.11B | $10.50B | $8.23B | $12.17B | $10.22B | $10.91B | $23.38B | $9.80B | $8.83B | $9.37B | $8.57B | $9.55B | $9.01B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $425M | · | $280M | $282M | $288M | · | $299M | |
| Interest Income | $101M | $104M | $148M | $161M | $139M | $138M | $114M | $94M | $87M | $183M | $145M | $107M | $95M | $102M | $82M | $52M | |
| Other Non-op | $61M | $-32M | $51M | $108M | $-494M | $-339M | $-305M | $-234M | $-273M | $-81M | $371M | $258M | $116M | $413M | $217M | $140M | |
| Pretax Income | $4.09B | $3.24B | $1.47B | $3.11B | $1.77B | $2.97B | $175M | $1.68B | $1.29B | $-11.52B | $1.67B | $2.14B | $1.86B | $2.77B | $1.86B | $2.21B | |
| Income Tax | $770M | $561M | $384M | $919M | $460M | $509M | $99M | $461M | $-398M | $392M | $-88M | $203M | $-218M | $503M | $-166M | $601M | |
| Net Income | $3.32B | $2.68B | $1.09B | $2.20B | $1.31B | $2.46B | $72M | $1.21B | $1.68B | $-11.91B | $1.76B | $1.93B | $2.07B | $2.26B | $2.02B | $1.61B | |
| EPS (Basic) | $1.62 | $1.31 | $0.54 | $1.08 | $0.64 | $1.21 | $0.05 | $0.60 | $0.83 | $-5.89 | $0.87 | $0.94 | $0.99 | $1.08 | $0.95 | $0.75 | |
| EPS (Diluted) | $1.62 | $1.31 | $0.54 | $1.08 | $0.64 | $1.20 | $0.05 | $0.60 | $0.83 | $-5.89 | $0.87 | $0.93 | $0.99 | $1.07 | $0.95 | $0.75 | |
| Shares (Basic) | 2,042,000,000 | 2,038,000,000 | -4,068,000,000 | 2,036,000,000 | 2,035,000,000 | 2,031,000,000 | -4,051,000,000 | 2,028,000,000 | 2,027,000,000 | 2,023,000,000 | -4,180,000,000 | 2,057,000,000 | 2,093,000,000 | 2,099,000,000 | -4,282,000,000 | 2,133,000,000 | |
| Shares (Diluted) | 2,048,000,000 | 2,047,000,000 | -4,078,000,000 | 2,039,000,000 | 2,038,000,000 | 2,040,000,000 | -4,056,000,000 | 2,031,000,000 | 2,029,000,000 | 2,023,000,000 | -4,201,000,000 | 2,064,000,000 | 2,102,000,000 | 2,113,000,000 | -4,315,000,000 | 2,148,000,000 | |
| EBITDA | · | $594M | · | · | · | $1.01B | · | · | · | $2.53B | · | · | · | $2.43B | · | · |
الميزانية العمومية 29
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.72B | $9.57B | $10.21B | $15.73B | $12.60B | $10.88B | $10.35B | $7.89B | $6.29B | $9.33B | · | $7.51B | $8.37B | $8.99B | · | $7.73B | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | $171M | $358M | $274M | · | $1.29B | |
| Receivables | $9.08B | $7.95B | $9.59B | $9.62B | $9.71B | $9.06B | $9.01B | $9.32B | $9.75B | $8.83B | · | $8.41B | $8.12B | $7.85B | · | $8.02B | |
| Inventory | $2.74B | $2.76B | $2.69B | $2.76B | $2.74B | $2.67B | $2.56B | $3.33B | $3.08B | $2.98B | · | $2.44B | $2.36B | $2.60B | · | $2.07B | |
| Other Current Assets | $4.22B | $4.60B | $4.61B | $4.95B | $5.47B | $5.53B | $5.62B | $5.62B | $5.74B | $5.57B | · | $7.21B | $6.87B | $5.16B | · | $6.08B | |
| Current Assets | $28.58B | $27.21B | $29.39B | $35.63B | $33.22B | $30.78B | $29.78B | $28.07B | $26.89B | $28.67B | · | $27.63B | $28.07B | $27.09B | · | $26.80B | |
| PP&E (Net) | $7.79B | $7.66B | $7.54B | $7.35B | $7.37B | $7.21B | $7.14B | $6.90B | $6.84B | $6.75B | · | $6.48B | $6.36B | $6.28B | · | $6.04B | |
| PP&E (Gross) | $13.34B | $13.09B | $12.84B | $12.54B | $12.68B | $12.32B | $12.09B | $11.74B | $11.93B | $11.69B | · | $11.13B | $10.83B | $10.52B | · | $10.17B | |
| Accum. Depreciation | $5.55B | $5.43B | $5.29B | $5.20B | $5.31B | $5.11B | $4.95B | $4.84B | $5.09B | $4.94B | · | $4.65B | $4.48B | $4.24B | · | $4.14B | |
| Goodwill | $21.74B | $21.74B | $21.75B | $21.75B | $21.78B | $21.74B | $21.72B | $21.75B | $21.73B | $21.74B | $21.17B | $21.15B | $21.16B | $21.16B | $21.15B | $21.11B | |
| Intangibles | $17.39B | $18.24B | $19.10B | $20.46B | $21.38B | $22.49B | $23.31B | $26.96B | $29.43B | $32.76B | · | $28.95B | $31.30B | $33.57B | · | $38.18B | |
| Other Non-current Assets | $6.38B | $6.08B | $6.47B | $6.33B | $5.94B | $5.87B | $6.11B | $6.04B | $6.07B | $6.02B | · | $5.21B | $5.02B | $4.87B | · | $4.75B | |
| Total Assets | $87.63B | $86.48B | $90.04B | $96.89B | $94.68B | $92.43B | $92.60B | $93.67B | $94.65B | $99.03B | · | $91.26B | $93.49B | $94.28B | · | $98.20B | |
| Accounts Payable | $4.16B | $4.23B | $3.58B | $4.29B | $5.43B | $4.00B | $3.60B | $3.47B | $3.75B | $3.54B | · | $2.81B | $3.07B | $3.19B | · | $2.60B | |
| Short-term Debt | $1.03B | $2.31B | $2.26B | $4.51B | $4.71B | $3.55B | $2.05B | $1.08B | $3.53B | $6.19B | · | $5.47B | $3.02B | $2.75B | · | $2.13B | |
| Current Liabilities | $18.66B | $19.16B | $23.42B | $28.14B | $27.53B | $24.07B | $23.77B | $22.64B | $23.27B | $25.82B | · | $23.46B | $20.15B | $19.09B | · | $18.93B | |
| Capital Leases | $1.73B | $1.77B | $1.83B | $1.85B | $1.55B | $1.36B | $1.37B | $1.48B | $1.44B | $1.56B | · | $1.51B | $1.34B | $1.37B | · | $845M | |
| Deferred Tax | $222M | $211M | $222M | $225M | $247M | $276M | $369M | $430M | $461M | $442M | · | $399M | $751M | $1.57B | · | $2.88B | |
| Other Non-current Liabilities | $4.34B | $4.85B | $5.04B | $5.46B | $4.94B | $4.48B | $4.47B | $4.73B | $4.99B | $6.73B | · | $6.20B | $5.90B | $6.66B | · | $6.68B | |
| Total Liabilities | $65.31B | $66.37B | $71.53B | $78.29B | $77.19B | $74.98B | $76.22B | $76.47B | $77.58B | $82.48B | · | $62.20B | $61.46B | $62.40B | · | $65.46B | |
| Long-term Debt | $42.86B | $44.14B | $44.83B | $48.72B | $48.95B | $49.51B | $49.43B | $49.55B | $51.95B | $52.36B | · | $37.01B | $37.07B | $37.33B | · | $38.87B | |
| Total Debt | $43.89B | $46.45B | · | $53.23B | $53.66B | $53.06B | · | $50.62B | $55.48B | $58.55B | · | $42.48B | $40.09B | $40.08B | · | $41.00B | |
| Common Stock | · | · | · | · | · | · | · | · | · | · | · | · | $292M | $292M | · | $292M | |
| Paid-in Capital | $46.50B | $46.37B | $46.39B | $46.27B | $46.13B | $46.01B | $46.02B | $45.90B | $45.77B | $45.66B | · | $44.85B | $45.30B | $45.14B | · | $44.96B | |
| Retained Earnings | $20.32B | $18.29B | $16.90B | $17.09B | $16.15B | $16.11B | $14.91B | $16.10B | $16.10B | $15.64B | · | $28.22B | $27.45B | $26.57B | · | $24.68B | |
| Treasury Stock | $43.50B | $43.52B | $43.58B | $43.59B | $43.59B | $43.60B | $43.66B | $43.67B | $43.69B | $43.70B | · | $43.08B | $39.68B | $38.81B | · | $36.41B | |
| AOCI | $-1.29B | $-1.37B | $-1.52B | $-1.51B | $-1.55B | $-1.42B | $-1.24B | $-1.47B | $-1.46B | $-1.40B | · | $-1.29B | $-1.39B | $-1.37B | · | $-841M | |
| Stockholders' Equity | $22.32B | $20.07B | $18.47B | $18.55B | $17.43B | $17.39B | $16.34B | $17.14B | $17.02B | $16.49B | · | $29.00B | $31.97B | $31.82B | · | $32.67B | |
| Liabilities + Equity | $87.63B | $86.48B | $90.04B | $96.89B | $94.68B | $92.43B | $92.60B | $93.67B | $94.65B | $99.03B | · | $91.26B | $93.49B | $94.28B | · | $98.20B |
التدفق النقدي 19
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $594M | $594M | $977M | $1.01B | $1.01B | $1.01B | $1.88B | $2.59B | $2.60B | $2.53B | $2.46B | $2.44B | $2.43B | $2.43B | $2.52B | $2.59B | |
| Stock-based Comp | $135M | $146M | $133M | $139M | $137M | $144M | $120M | $129M | $125M | $133M | $127M | $132M | $137M | $122M | $119M | $115M | |
| Deferred Tax | $-195M | $161M | $-392M | $-359M | $-437M | $223M | $-791M | $-256M | $-331M | $-711M | $-1.33B | $-327M | $-1.09B | $-548M | $-624M | $-645M | |
| Amort. of Intangibles | $471M | $472M | $906M | $867M | $864M | $863M | $1.80B | $2.40B | $2.40B | $2.40B | $2.30B | $2.30B | $2.30B | $2.30B | $2.30B | $2.50B | |
| Restructuring | $56M | $5M | $132M | $75M | $223M | $133M | $77M | $78M | $260M | $220M | $44M | $141M | $113M | $67M | $15M | $17M | |
| Other Non-cash | · | $-2.47B | · | · | · | $-1.88B | · | · | · | $12.79B | · | · | · | $-1.29B | · | · | |
| Operating Cash Flow | $3.39B | $1.10B | $1.97B | $6.31B | $3.92B | $1.95B | $4.44B | $5.59B | $2.33B | $2.83B | $4.25B | $4.75B | $1.89B | $2.97B | $3.31B | $3.69B | |
| CapEx | $305M | $347M | $370M | $320M | $361M | $260M | $378M | $324M | $262M | $284M | $330M | $342M | $259M | $278M | $346M | $247M | |
| Investing Cash Flow | $-1.61B | $-131M | $-1.46B | $-1.70B | $-473M | $-499M | $-196M | $-219M | $-1.32B | $-19.62B | $-1.35B | $-410M | $-329M | $-210M | $1.21B | $-2.08B | |
| Debt Issued | · | · | $5.74B | $0 | $0 | $0 | $0 | $0 | $0 | $12.88B | · | · | · | · | $26M | $0 | |
| Net Debt Issued | · | $-500M | · | · | · | $0 | · | · | · | $0 | · | · | · | $-1.64B | · | · | |
| Stock Repurchased | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $4.00B | $905M | $250M | $2.42B | $701M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $-250M | · | $-701M | |
| Dividends Paid | $1.29B | $1.28B | $1.26B | $1.26B | $1.26B | $1.26B | $1.22B | $1.22B | $1.22B | $1.21B | $1.16B | $1.19B | $1.20B | $1.20B | $1.15B | $1.15B | |
| Financing Cash Flow | $-2.63B | $-1.56B | $-6.03B | $-1.49B | $-1.84B | $-993M | $-1.64B | $-3.85B | $-4.02B | $14.64B | $967M | $-5.16B | $-2.17B | $-3.05B | $-3.25B | $-4.54B | |
| Net Change in Cash | $-861M | $-635M | $-5.51B | $3.12B | $1.74B | $528M | $2.45B | $1.60B | $-3.04B | $-2.19B | $3.95B | $-857M | $-623M | $-277M | $1.37B | $-3.00B | |
| Taxes Paid | · | $239M | $1.06B | $400M | $1.56B | $235M | $800M | $1.00B | $1.91B | $187M | $200M | $1.00B | $2.95B | $149M | $1.50B | $1.20B | |
| Free Cash Flow | · | $757M | · | · | · | $1.69B | · | · | · | $2.55B | · | · | · | $2.69B | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $2.11B | · | · | · | $2.46B | · | · |
الربحية 5
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 25.6% | 23.3% | · | 18.0% | 10.7% | 21.9% | · | 10.2% | 13.8% | -100.4% | · | 17.6% | 18.5% | 20.0% | · | 14.3% | |
| Pretax Margin | 31.5% | 28.2% | · | 25.5% | 14.4% | 26.5% | · | 14.1% | 10.5% | -97.1% | · | 19.5% | 16.6% | 24.4% | · | 19.7% | |
| EBITDA Margin | · | 5.2% | · | · | · | 9.0% | · | · | · | 21.3% | · | · | · | 21.4% | · | · | |
| ROA | 3.6% | 3.0% | · | 2.3% | 1.4% | 2.6% | · | 1.3% | 1.8% | -12.3% | · | 2.0% | 2.1% | 2.3% | · | 1.5% | |
| ROE | 16.7% | 14.3% | · | 12.3% | 7.6% | 14.5% | · | 5.2% | 6.9% | -49.3% | · | 6.2% | 6.4% | 7.1% | · | 4.6% |
السيولة والملاءة 4
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.5 | 1.4 | · | 1.3 | 1.2 | 1.3 | · | 1.2 | 1.2 | 1.1 | · | 1.2 | 1.4 | 1.4 | · | 1.4 | |
| Quick Ratio | 1.0 | 0.9 | · | 0.9 | 0.8 | 0.8 | · | 0.8 | 0.7 | 0.7 | · | 0.7 | 0.8 | 0.9 | · | 0.9 | |
| Debt / Equity | 2.0 | 2.3 | · | 2.9 | 3.1 | 3.1 | · | 3.0 | 3.3 | 3.6 | · | 1.5 | 1.3 | 1.3 | · | 1.3 | |
| LT Debt / Equity | 1.9 | 2.1 | · | 2.4 | 2.6 | 2.7 | · | 2.8 | 2.9 | 3.0 | · | 1.1 | 1.1 | 1.1 | · | 1.1 |
الكفاءة 3
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 1.4 | 1.3 | · | 1.1 | 1.2 | 1.1 | · | 1.0 | 1.2 | 1.0 | · | 1.1 | 1.3 | 1.1 | · | 1.1 | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | 1.4 | 1.4 | · | 1.3 | 1.4 | 1.5 | · | 1.4 |
التقييم (آخر 12 شهرًا) 5
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $48.95B | $47.18B | · | $47.58B | $47.56B | $47.16B | · | $46.92B | $46.26B | $45.39B | · | $44.75B | $45.67B | $46.09B | · | $46.38B | |
| Net Income TTM | $9.51B | $8.64B | · | $7.18B | $6.66B | $-6.56B | · | $-7.09B | $-6.23B | $-5.65B | · | $7.87B | $7.36B | $6.57B | · | $5.85B | |
| P/E | 12.4 | 14.3 | · | 12.8 | 14.2 | -18.7 | · | -14.7 | -13.2 | -18.7 | · | 15.5 | 18.4 | 22.6 | · | 26.4 | |
| Earnings Yield | 8.1% | 7.0% | · | 7.8% | 7.1% | -5.3% | · | -6.8% | -7.6% | -5.3% | · | 6.4% | 5.4% | 4.4% | · | 3.8% | |
| Payout Ratio | · | 47.9% | · | · | · | 51.2% | · | · | · | -10.2% | · | · | · | 52.9% | · | · |
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
قائمة الدخل
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الإيرادات | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B |
| صافي الدخل | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B |
| EPS المخفف | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 |
الميزانية العمومية
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الدين / حقوق الملكية | 2.5 | 3.2 | 1.4 | 1.4 | 1.4 |
| النسبة الحالية | 1.3 | 1.3 | 1.4 | 1.2 | 1.5 |
| النسبة السريعة | 0.8 | 0.8 | 0.9 | 0.8 | 1.1 |
التدفق النقدي
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| التدفق النقدي الحر | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B |
آخر الأخبار أحدث العناوين التي تذكر هذه الشركة
- Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
- Bristol Myers Squibb to build $2.3 billion Houston campus
- Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
- The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today
- Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca
- $400 Billion Pharma Megadeal? Jefferies Calls Potential AstraZeneca-Bristol Myers Merger A "Head Scratcher"
- AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
- Bill Ackman Runs a $14 Billion Fund on Just 11 Stocks. These Are His 3 Biggest Bets Right Now.
- Is Bristol-Myers Squibb Stock Underperforming the Dow?
- Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now?
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
📊
اختر المقاييس التي تهمك — انقر فوق علامة ➕ بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.
الملاك المؤسسيون (13F) 2785 مقدمي إقرار · $58.1B إجمالي · حتى تاريخ 30 يونيو، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
النشاط المؤسسي — Q2 2026 مقابل الربع السابق
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 159 (-159 مقابل الربع السابق) | 154 (+18 مقابل الربع السابق) | 1006 (-29 مقابل الربع السابق) | 987 (+89 مقابل الربع السابق) | +55.3M |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $7682927263 | 133337856 | 13,22% | الأسهم |
| STATE STREET CORP | $5900803123 | 102408940 | 10,15% | الأسهم |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $3894809793 | 67594755 | 6,70% | الأسهم |
| GEODE CAPITAL MANAGEMENT, LLC | $2858273235 | 49750183 | 4,92% | الأسهم |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2700823125 | 46873015 | 4,65% | الأسهم |
| NORGES BANK | $2124256834 | 36866658 | 3,66% | الأسهم |
| PRIMECAP MANAGEMENT CO/CA/ | $1436115120 | 24923900 | 2,47% | الأسهم |
| AMERIPRISE FINANCIAL INC | $1308030705 | 22705049 | 2,25% | الأسهم |
| Independent Franchise Partners LLP | $1255703498 | 21792841 | 2,16% | الأسهم |
| DIMENSIONAL FUND ADVISORS LP | $938463230 | 16287109 | 1,61% | الأسهم |
| VANGUARD FIDUCIARY TRUST CO | $660776941 | 11467840 | 1,14% | الأسهم |
| VICTORY CAPITAL MANAGEMENT INC | $585933423 | 10168924 | 1,01% | الأسهم |
| TWO SIGMA INVESTMENTS, LP | $581119768 | 10085383 | 1,00% | الأسهم |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $494716447 | 8585846 | 0,85% | الأسهم |
| BlackRock, Inc. | $492399085 | 8545628 | 0,85% | الأسهم |
| FMR LLC | $451250223 | 7831486 | 0,78% | الأسهم |
| TWO SIGMA ADVISERS, LP | $446094588 | 8270200 | 0,77% | الأسهم |
| Robeco Institutional Asset Management B.V. | $417435581 | 7244630 | 0,72% | الأسهم |
| GOLDMAN SACHS GROUP INC | $392167333 | 6806097 | 0,67% | الأسهم |
| FIRST TRUST ADVISORS LP | $344672508 | 5981822 | 0,59% | الأسهم |
| Capital International Investors | $340767005 | 5913752 | 0,59% | الأسهم |
| Swiss National Bank | $331822056 | 5758800 | 0,57% | الأسهم |
| VAN ECK ASSOCIATES CORP | $325076944 | 5641738 | 0,56% | الأسهم |
| National Pension Service | $321412139 | 5578135 | 0,55% | الأسهم |
| Mitsubishi UFJ Asset Management Co., Ltd. | $319229612 | 5540268 | 0,55% | الأسهم |
| BNP PARIBAS FINANCIAL MARKETS | $316480270 | 5492542 | 0,54% | الأسهم |
| Legal & General Group Plc | $315258552 | 5471339 | 0,54% | الأسهم |
| M&G PLC | $306949282 | 5292229 | 0,53% | الأسهم |
| NORDEA INVESTMENT MANAGEMENT AB | $300773017 | 5232200 | 0,52% | الأسهم |
| Sumitomo Mitsui Trust Group, Inc. | $293408012 | 5092121 | 0,50% | الأسهم |
| ALLIANCEBERNSTEIN L.P. | $288555718 | 4757720 | 0,50% | الأسهم |
| Vanguard Global Advisers, LLC | $270856466 | 4700737 | 0,47% | الأسهم |
| VANGUARD ASSET MANAGEMENT, Ltd | $266201519 | 4619950 | 0,46% | الأسهم |
| California Public Employees Retirement System | $263375546 | 4570905 | 0,45% | الأسهم |
| BANK OF AMERICA CORP /DE/ | $263115723 | 4566396 | 0,45% | الأسهم |
| VANGUARD GROUP INC | $247970649 | 4597157 | 0,43% | الأسهم |
| Caisse de depot et placement du Quebec | $243646343 | 4228503 | 0,42% | الأسهم |
| CANADA PENSION PLAN INVESTMENT BOARD | $241222903 | 4186444 | 0,42% | الأسهم |
| JANE STREET GROUP, LLC | $224896622 | 3903100 | 0,39% | عقد خيار الشراء |
| WELLINGTON MANAGEMENT GROUP LLP | $214546630 | 3723475 | 0,37% | الأسهم |
| Employees Provident Fund Board | $209755987 | 3640333 | 0,36% | الأسهم |
| CITADEL ADVISORS LLC | $194502072 | 3375600 | 0,33% | عقد خيار البيع |
| RHUMBLINE ADVISERS | $192874042 | 3347347 | 0,33% | الأسهم |
| LPL Financial LLC | $188151217 | 3265381 | 0,32% | الأسهم |
| BARCLAYS PLC | $186163076 | 3230876 | 0,32% | الأسهم |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $185255963 | 3215133 | 0,32% | الأسهم |
| UBS Group AG | $180243196 | 3128136 | 0,31% | الأسهم |
| Qube Research & Technologies Ltd | $178273860 | 3093958 | 0,31% | الأسهم |
| Artemis Investment Management LLP | $175941518 | 3053480 | 0,30% | الأسهم |
| SEB Asset Management AB | $165520833 | 2872632 | 0,28% | الأسهم |
| Ensign Peak Advisors, Inc | $165119502 | 2865663 | 0,28% | الأسهم |
| CITADEL ADVISORS LLC | $157769322 | 2738100 | 0,27% | عقد خيار الشراء |
| JANE STREET GROUP, LLC | $152525902 | 2647100 | 0,26% | عقد خيار البيع |
| NATIXIS | $145152674 | 2519137 | 0,25% | الأسهم |
| AustralianSuper Pty Ltd | $140209857 | 2433354 | 0,24% | الأسهم |
| Mirae Asset Global Investments Co., Ltd. | $138044440 | 2395773 | 0,24% | الأسهم |
| Bank of New York Mellon Corp | $136334163 | 2366091 | 0,23% | الأسهم |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $132803901 | 2304823 | 0,23% | الأسهم |
| PANAGORA ASSET MANAGEMENT INC | $132622456 | 2301674 | 0,23% | الأسهم |
| Capital World Investors | $129313224 | 2244242 | 0,22% | الأسهم |
| NEW YORK STATE COMMON RETIREMENT FUND | $129300432 | 2244020 | 0,22% | الأسهم |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $125419207 | 2176661 | 0,22% | الأسهم |
| RAYMOND JAMES FINANCIAL INC | $123353032 | 2140802 | 0,21% | الأسهم |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $122879893 | 2132591 | 0,21% | الأسهم |
| PFA Pension, Forsikringsaktieselskab | $121829832 | 2114367 | 0,21% | الأسهم |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $120528714 | 2234496 | 0,21% | الأسهم |
| MACKENZIE FINANCIAL CORP | $118944044 | 2064284 | 0,20% | الأسهم |
| Pictet Asset Management Holding SA | $116783155 | 2026687 | 0,20% | الأسهم |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $116161574 | 2015994 | 0,20% | الأسهم |
| TD Asset Management Inc | $115669154 | 2007448 | 0,20% | الأسهم |
| SUSQUEHANNA ADVISORS GROUP, INC. | $115240000 | 2000000 | 0,20% | عقد خيار الشراء |
| MACQUARIE GROUP LTD | $111978478 | 1943396 | 0,19% | الأسهم |
| Vinva Investment Management Ltd | $109557913 | 1870866 | 0,19% | الأسهم |
| ENVESTNET ASSET MANAGEMENT INC | $108509833 | 1883218 | 0,19% | الأسهم |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $106751521 | 1760124 | 0,18% | الأسهم |
| LMR Partners LLP | $106066896 | 1840800 | 0,18% | عقد خيار البيع |
| AVIVA PLC | $103620639 | 1798345 | 0,18% | الأسهم |
| PRUDENTIAL FINANCIAL INC | $103202606 | 1791090 | 0,18% | الأسهم |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $102378000 | 1776782 | 0,18% | الأسهم |
| STOREBRAND ASSET MANAGEMENT AS | $101037131 | 1753508 | 0,17% | الأسهم |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $100790172 | 1749222 | 0,17% | الأسهم |
| BANK OF NOVA SCOTIA | $99453647 | 1726026 | 0,17% | الأسهم |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $98875920 | 1716000 | 0,17% | الأسهم |
| KLP KAPITALFORVALTNING AS | $94673002 | 1643058 | 0,16% | الأسهم |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $90576678 | 1567009 | 0,16% | الأسهم |
| BANK OF MONTREAL /CAN/ | $89684378 | 1556480 | 0,15% | الأسهم |
| Douglas Lane & Associates, LLC | $89667305 | 1556184 | 0,15% | الأسهم |
| PNC Financial Services Group, Inc. | $89112096 | 1546548 | 0,15% | الأسهم |
| Walleye Trading LLC | $88014550 | 1527500 | 0,15% | عقد خيار الشراء |
| Korea Investment CORP | $86518389 | 1501534 | 0,15% | الأسهم |
| APG Asset Management N.V. | $85242422 | 1691386 | 0,15% | الأسهم |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $85175958 | 1478236 | 0,15% | الأسهم |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $84205059 | 1764695 | 0,14% | الأسهم |
| Mariner, LLC | $83309670 | 1445809 | 0,14% | الأسهم |
| Retirement Systems of Alabama | $80928212 | 1404516 | 0,14% | الأسهم |
| AMERICAN CENTURY COMPANIES INC | $80695542 | 1400478 | 0,14% | الأسهم |
| Nuveen Asset Management, LLC | $76733142 | 1356668 | 0,13% | الأسهم |
| CWM, LLC | $76220909 | 1256734 | 0,13% | الأسهم |
| Eurizon Capital SGR S.p.A. | $70986984 | 1230296 | 0,12% | الأسهم |
| Aberdeen Group plc | $70798674 | 1228717 | 0,12% | الأسهم |
المطلعون على الشركة 102 من المطلعين · مسؤولون 65 · مديرون 37
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| Christopher S. Boerner | Chief Executive Officer | 13 يونيو، 2025 G | 125439 | 0 | 0 | $0 |
| Peter R Dolan | Former CEO | 8 سبتمبر، 2006 F | 571673 | 0 | 0 | $0 |
| David V Elkins | EVP, Chief Financial Officer | 1 إبريل، 2026 S | 159248 | 0 | 3 | $-4500496 |
| Jean-Marc Huet | EVP & CFO | 30 إبريل، 2009 P | 25000 | 0 | 0 | $0 |
| Benjamin Hickey | President, RayzeBio Org. | 9 مايو، 2025 S | 0 | 0 | 0 | $0 |
| Lynelle Hoch | President, Cell Therapy Org. | 10 مارس، 2025 A | 4711 | 0 | 0 | $0 |
| James B D Palmer DR | CSO & President, PRI | 2 مارس، 2004 A | 178889 | 0 | 0 | $0 |
| Dean J Mitchell | President, U.S. Primary Care | 10 سبتمبر، 2003 A | 60000 | 0 | 0 | $0 |
| Cristian Massacesi | EVP,Chief Med Offr,Head of Dev | 1 أغسطس، 2026 M | 24997 | 0 | 0 | $0 |
| Cari Gallman | EVP, General Counsel | 1 أغسطس، 2026 M | 13649 | 0 | 0 | $0 |
| Bartie Wendy Short | EVP, Corporate Affairs | 3 يونيو، 2026 F | 12081 | 0 | 0 | $0 |
| Hiroshi Chris Shibutani | EVP, Chief Strategy Officer | 1 يوليو، 2025 A | — | 0 | 0 | $0 |
| Adam Lenkowsky | EVP, Chief Commercial Officer | 1 مايو، 2025 J | 12439 | 0 | 0 | $0 |
| Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 25 إبريل، 2025 P | 83513 | 0 | 0 | $0 |
| Karin Shanahan | EVP, Glob. Prod. Dev. & Supply | 1 إبريل، 2025 M | 13797 | 0 | 0 | $0 |
| Phil M Holzer | SVP and Controller | 10 مارس، 2025 A | 14967 | 0 | 0 | $0 |
| Ahn Amanda Poole | EVP, Chief People Officer | 10 مارس، 2025 A | 5196 | 0 | 0 | $0 |
| Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | 10 مارس، 2025 A | 16102 | 0 | 0 | $0 |
| Robert M Plenge | EVP, Chief Research Officer | 10 مارس، 2025 A | 15839 | 0 | 0 | $0 |
| Sandra Leung | EVP, General Counsel | 10 مارس، 2025 A | 364296 | 0 | 0 | $0 |
| Giovanni Caforio | Executive Chair of the Board | 10 مارس، 2024 M | 432266 | 0 | 0 | $0 |
| Ann Powell Judge | EVP, Chief Human Resources | 24 أغسطس، 2023 S | 27868 | 0 | 0 | $0 |
| Michelle Weese | EVP, Corporate Affairs | 1 يوليو، 2023 M | 3453 | 0 | 0 | $0 |
| Rupert Vessey | EVP & President, Research | 3 مايو، 2023 S | 47751 | 0 | 0 | $0 |
| Sharon Greenlees | SVP & Controller | 2 مايو، 2023 M | 609 | 0 | 0 | $0 |
| Elizabeth Mily | EVP, Strategy & BD | 1 إبريل، 2023 M | 34734 | 0 | 0 | $0 |
| Karen Murphy Santiago | SVP & Controller | 14 مارس، 2022 S | 16704 | 0 | 0 | $0 |
| Paul Von Autenried | EVP, Chief Information Officer | 24 نوفمبر، 2021 S | 63536 | 0 | 0 | $0 |
| Adam Dubow | SVP,ChiefCompliance&EthicsOff. | 30 يوليو، 2021 S | 13777 | 0 | 0 | $0 |
| Joseph Eid | SVP,Head Glob. Medical Affairs | 3 يونيو، 2021 M | 9485 | 0 | 0 | $0 |
| Louis S Schmukler | EVP,Pres.,Glob.Prod. & Supply | 10 مايو، 2021 S | 31956 | 0 | 0 | $0 |
| Kathryn Metcalfe | EVP, Corporate Affairs | 10 مارس، 2020 A | — | 0 | 0 | $0 |
| John E Elicker | EVP, Investor Relations | 10 مارس، 2020 M | 70946 | 0 | 0 | $0 |
| Charles A Bancroft | EVP, Head of Integration | 10 مارس، 2020 M | 137534 | 0 | 0 | $0 |
| Paul Biondi | SVP, Head of Strategy & BD | 2 أكتوبر، 2019 M | 6214 | 0 | 0 | $0 |
| Thomas J. Lynch Jr. | EVP & Chief Scientific Officer | 3 إبريل، 2019 M | 22223 | 0 | 0 | $0 |
| Murdo Gordon | EVP, Chief Commercial Officer | 1 أغسطس، 2018 M | 49424 | 0 | 0 | $0 |
| Joseph C Caldarella | SVP & Controller | 6 سبتمبر، 2017 S | 46297 | 0 | 0 | $0 |
| Anne Nielsen | Chief Compliance & Ethics Off | 3 سبتمبر، 2017 M | 37974 | 0 | 0 | $0 |
| Emmanuel Blin | SVP, Chief Strategy Officer | 10 مارس، 2017 A | 20138 | 0 | 0 | $0 |
| Francis M Cuss | EVP & CSO | 10 مارس، 2017 M | 321906 | 0 | 0 | $0 |
| Samuel J Moed | SVP, Strat Plan & Analysis | 13 مارس، 2015 S | 31015 | 0 | 0 | $0 |
| Brian Daniels | SVP Global Dev & Med Affairs | 1 يوليو، 2014 M | 94374 | 0 | 0 | $0 |
| Frances K Heller | SVP, Business Development | 10 مارس، 2014 A | 4174 | 0 | 0 | $0 |
| Elliot Sigal | EVP, CSO & President R&D | 3 يونيو، 2013 M | 148221 | 0 | 0 | $0 |
| Beatrice J Cazala | EVP Commercial Operations | 31 مايو، 2013 S | 173375 | 0 | 0 | $0 |
| John E Celentano | SVP HR Public Affairs & Philan | 6 مارس، 2012 M | 142142 | 0 | 0 | $0 |
| Jeremy M Levin | SVP Strat Transactions | 1 أكتوبر، 2011 M | 43689 | 0 | 0 | $0 |
| De Notaristefani Carlo | Pres Tech Ops & Supp Fnctns | 14 يونيو، 2011 M | 7578 | 0 | 0 | $0 |
| Anthony C Hooper | SVP ComOps Pres USJap Int | 13 مايو، 2011 M | 203170 | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
الناشطون والمالكون بنسبة 5%+ 11 حيازة
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY, CELGENE CORPORATION ×3 إيداعات | 16 يوليو، 2020 | — | إيداع أولي | — | SEC |
| Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, Wellington Management Company LLP | 27 فبراير، 2019 | — | إيداع أولي | استثمار سلبي | SEC |
| S.S. OR ×3 إيداعات | 23 ديسمبر، 2009 | — | إيداع أولي | — | SEC |
| Medarex, Inc. S.S. OR, S.S. OR | 25 نوفمبر، 2009 | — | إيداع أولي | — | SEC |
| Identification Nos. of Above Persons (entities only) Bristol-Myers Squibb Company ×2 إيداعات | 27 فبراير، 2009 | — | إيداع أولي | — | SEC |
| Bristol -Myers Squibb Company, Bristol -Myers Squibb Biologics Company ×3 إيداعات | 8 أكتوبر، 2008 | — | إيداع أولي | — | SEC |
| Bristol-Myers Squibb Company I.R.S. Employer Identification Number 22-079-0350 ×3 إيداعات | 6 يونيو، 2003 | — | إيداع أولي | — | SEC |
| شخص مُبلِّغ لم يُكشف عنه | 16 إبريل، 2003 | — | إيداع أولي | — | SEC |
| شخص مُبلِّغ لم يُكشف عنه | 3 فبراير، 2003 | — | إيداع أولي | — | SEC |
| شخص مُبلِّغ لم يُكشف عنه | 6 مارس، 2002 | — | إيداع أولي | — | SEC |
| شخص مُبلِّغ لم يُكشف عنه | 6 فبراير، 2002 | — | إيداع أولي | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 296 صناديق مؤشرات متداولة
الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.
| صندوق | الوزن | الوحدات | حتى تاريخ | المصدر |
|---|---|---|---|---|
| FTXH · First Trust Exchange-Traded Fund VI | 6,29% | 39590 NS | 30 يونيو، 2026 | N-PORT |
| RDIV · Invesco Exchange-Traded Fund Trust … | 5,25% | 1134150 SH | 21 أغسطس، 2026 | يومي |
| ROPE · EA Series Trust | 4,97% | 7379 NS | 29 مايو، 2026 | N-PORT |
| IHE · iShares Trust | 4,65% | 1223984 SH | 21 أغسطس، 2026 | يومي |
| CAMX · ADVISORS' INNER CIRCLE FUND | 4,10% | 44768 NS | 30 إبريل، 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 3,50% | 6427 NS | 30 إبريل، 2026 | N-PORT |
| FDL · First Trust Exchange-Traded Fund | 3,43% | 4337329 NS | 30 يونيو، 2026 | N-PORT |
| CANC · Tema ETF Trust | 3,30% | 101680 NS | 31 مايو، 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 3,21% | 2332 NS | 30 إبريل، 2026 | N-PORT |
| AGNG · Global X Funds | 2,98% | 42594 NS | 31 مايو، 2026 | N-PORT |
| SCHD · SCHWAB STRATEGIC TRUST | 2,93% | 48641121 NS | 31 مايو، 2026 | N-PORT |
| PJP · Invesco Exchange-Traded Fund Trust | 2,78% | 224546 SH | 21 أغسطس، 2026 | يومي |
| ABFL · Abacus FCF ETF Trust | 2,76% | 226688 NS | 30 إبريل، 2026 | N-PORT |
| HDV · iShares Trust | 2,62% | 6134190 SH | 21 أغسطس، 2026 | يومي |
| ACEP · EA Series Trust | 2,52% | 44211 NS | 29 مايو، 2026 | N-PORT |
| SIXH · EXCHANGE TRADED CONCEPTS TRUST | 2,47% | 234394 NS | 31 مايو، 2026 | N-PORT |
| SIXA · EXCHANGE TRADED CONCEPTS TRUST | 2,47% | 210030 NS | 31 مايو، 2026 | N-PORT |
| VALQ · AMERICAN CENTURY ETF TRUST | 2,45% | 148728 NS | 31 مايو، 2026 | N-PORT |
| GEND · Spinnaker ETF Series | 2,18% | 1612 NS | 30 إبريل، 2026 | N-PORT |
| UPGD · Invesco Exchange-Traded Fund Trust | 2,10% | 38747 SH | 21 أغسطس، 2026 | يومي |
| HRTS · Tema ETF Trust | 2,09% | 18939 NS | 31 مايو، 2026 | N-PORT |
| FDIV · EA Series Trust | 2,07% | 24896 NS | 30 إبريل، 2026 | N-PORT |
| IYH · iShares Trust | 2,06% | 1218183 SH | 21 أغسطس، 2026 | يومي |
| SPHD · Invesco Exchange-Traded Fund Trust … | 2,06% | 1086835 SH | 21 أغسطس، 2026 | يومي |
| GCOW · Pacer Funds Trust | 2,03% | 1123894 NS | 30 إبريل، 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 2,03% | 6082360 NS | 30 إبريل، 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 2,03% | 15628 NS | 30 إبريل، 2026 | N-PORT |
| SPDV · ETF Series Solutions | 2,02% | 30055 NS | 30 إبريل، 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 1,99% | 938456 NS | 30 إبريل، 2026 | N-PORT |
| VLLU · Harbor ETF Trust | 1,98% | 1422 NS | 30 إبريل، 2026 | N-PORT |
| BMVP · Invesco Exchange-Traded Fund Trust | 1,93% | 31120 SH | 21 أغسطس، 2026 | يومي |
| PEY · Invesco Exchange-Traded Fund Trust | 1,83% | 327924 SH | 21 أغسطس، 2026 | يومي |
| SDOG · ALPS ETF Trust | 1,83% | 441820 NS | 31 مايو، 2026 | N-PORT |
| RFDA · ALPS ETF Trust | 1,82% | 27812 NS | 31 مايو، 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 1,78% | 40606 NS | 30 إبريل، 2026 | N-PORT |
| FLOW · Global X Funds | 1,78% | 8912 NS | 31 مايو، 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 1,73% | 6137665 SH | 19 أغسطس، 2026 | يومي |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,70% | 213437 SH | 21 أغسطس، 2026 | يومي |
| RXL · ProShares Trust | 1,68% | 21228 NS | 31 مايو، 2026 | N-PORT |
| GMOV · GMO ETF Trust | 1,66% | 26358 NS | 31 مايو، 2026 | N-PORT |
| VMAX · Lattice Strategies Trust | 1,65% | 12671 NS | 30 إبريل، 2026 | N-PORT |
| IXJ · iShares Trust | 1,61% | 1073117 SH | 21 أغسطس، 2026 | يومي |
| NULV · Nushares ETF Trust | 1,57% | 539514 NS | 30 إبريل، 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,54% | 13556 NS | 30 إبريل، 2026 | N-PORT |
| NUDV · Nushares ETF Trust | 1,54% | 11473 NS | 30 إبريل، 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1,47% | 415736 SH | 21 أغسطس، 2026 | يومي |
| COWG · Pacer Funds Trust | 1,47% | 526151 NS | 30 إبريل، 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 1,46% | 68134 NS | 30 إبريل، 2026 | N-PORT |
| TMFE · RBB Fund, Inc. | 1,45% | 21473 NS | 31 مايو، 2026 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1,43% | 64178 NS | 30 إبريل، 2026 | N-PORT |